ubmslateCN-logo-ubm

CN Mobile Logo

Topics:

Hematologic Malignancies

Melanoma Risk Increased in CLL/SLL Patients

Results of a new study have indicated that the risk of developing melanoma may be almost doubled among survivors of chronic lymphocytic leukemia/small lymphocytic lymphoma who were treated with certain chemotherapeutic agents or who had specific immune-related medical conditions.

Hematologic Malignancies

Daratumumab, a monoclonal antibody that targets CD38, was safe and effective in patients with heavily pretreated and refractory multiple myeloma.

A complex high-dose combination therapy is tolerable and effective in patients with aggressive B-cell lymphoma that has spread to the central nervous system.

Continuous therapy resulted in delays in first and second progression compared with fixed-duration therapy in patients with newly diagnosed multiple myeloma.

Researchers combined clinical risk factors with mutation status from seven genes to improve prognostication for patients with follicular lymphoma.

The Case: A 45-year-old man with a known history of rheumatic fever and aortic valve replacement 15 years earlier presented with the chief complaint of a 1-month history of progressive, intense, nonmechanical lumbar p

This article evaluates the most up-to-date peer-reviewed published work on the treatment of peripheral T-cell lymphoma, and offers a glimpse into the current upfront clinical trial landscape for patients affected by this uncommon disease.

Our standard therapies for peripheral T-cell lymphoma may cure a subset of patients, and thus far novel agents have not changed the outcomes for the majority.

Pages

Subscribe to Hematologic Malignancies on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.